Company news
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) news
Fennec Pharmaceuticals Inc. news releases on 6ix. Latest, Sep 17, 2026: Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results…
Press releases & updates
Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026
September 17, 2026
Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
August 11, 2026
Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026
August 5, 2026
Fennec Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
June 16, 2026
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
June 15, 2026
Fennec Pharmaceuticals : Announces Results of Annual Meeting
June 9, 2026
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
May 21, 2026
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
May 13, 2026
Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
May 8, 2026
Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
May 7, 2026
Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting
April 20, 2026
Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center
April 6, 2026
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 30, 2026
Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 23, 2026
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026
March 17, 2026
Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation
March 15, 2026
Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute
March 4, 2026
Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers
February 20, 2026
Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors
December 9, 2025
Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss
December 2, 2025
Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
November 26, 2025
Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption
November 19, 2025
Fennec Pharmaceuticals Announces Closing of Private Offering of Common Shares in Canada
November 18, 2025
Fennec Pharmaceuticals Announces Closing of Offering of Common Shares
November 17, 2025
Fennec Pharmaceuticals Announces Proposed Offering of Common Shares
November 13, 2025
Fennec Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
November 13, 2025
Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada
November 12, 2025
Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares
November 12, 2025
Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update
August 14, 2025
Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025
August 11, 2025
Fennec Announces Results of Annual Meeting
June 3, 2025
Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
May 13, 2025
Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
May 8, 2025
Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
March 10, 2025
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025
March 6, 2025
Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany
February 6, 2025
Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales
December 19, 2024
Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management
December 18, 2024
Fennec Pharmaceuticals to Participate in Upcoming Investor Conference
December 11, 2024
Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
November 6, 2024
Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
October 30, 2024
Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company’s Next Stage of Growth
October 27, 2024
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
September 4, 2024
Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024
August 5, 2024
Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director
August 4, 2024
Fennec Pharmaceuticals Announces Management Change
June 30, 2024
Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
May 13, 2024
Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024
May 6, 2024
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update
March 20, 2024